- Report
- February 2024
- 172 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- January 2024
- 182 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- November 2023
- 78 Pages
France
From €2611EUR$2,975USD£2,259GBP
€3072EUR$3,500USD£2,658GBP
- Report
- November 2023
- 83 Pages
Germany
From €2611EUR$2,975USD£2,259GBP
€3072EUR$3,500USD£2,658GBP
- Report
- November 2023
- 181 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- October 2023
- 128 Pages
North America
From €2984EUR$3,400USD£2,582GBP
€3510EUR$4,000USD£3,037GBP
- Report
- August 2023
- 111 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- March 2023
- 115 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- January 2023
- 77 Pages
United Kingdom
From €2611EUR$2,975USD£2,259GBP
€3072EUR$3,500USD£2,658GBP
- Report
- June 2024
- 183 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- June 2024
- 180 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- May 2024
- 187 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- May 2024
- 182 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- May 2024
- 185 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- May 2024
- 185 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- May 2024
- 185 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- April 2024
- 180 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- April 2024
- 180 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- November 2023
- 190 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP
- Report
- November 2023
- 190 Pages
Global
From €3357EUR$3,825USD£2,905GBP
€3949EUR$4,500USD£3,417GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more